SouthState Corp Sells 428 Shares of Eli Lilly and Company (NYSE:LLY)

SouthState Corp reduced its holdings in Eli Lilly and Company (NYSE:LLY) by 3.0% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 13,738 shares of the company’s stock after selling 428 shares during the quarter. SouthState Corp’s holdings in Eli Lilly and Company were worth $8,008,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of LLY. Lipe & Dalton bought a new stake in shares of Eli Lilly and Company in the 4th quarter valued at about $26,000. Thompson Investment Management Inc. bought a new stake in Eli Lilly and Company in the third quarter valued at approximately $27,000. Legacy Financial Group LLC bought a new stake in Eli Lilly and Company in the third quarter valued at approximately $35,000. Optiver Holding B.V. acquired a new stake in Eli Lilly and Company during the 3rd quarter valued at approximately $36,000. Finally, Family CFO Inc bought a new position in Eli Lilly and Company during the 3rd quarter worth approximately $40,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 2.8 %

Shares of NYSE:LLY traded down $20.94 during mid-day trading on Friday, hitting $734.97. 4,535,213 shares of the company traded hands, compared to its average volume of 3,087,178. The stock has a 50-day moving average price of $761.75 and a two-hundred day moving average price of $670.56. Eli Lilly and Company has a 12-month low of $419.80 and a 12-month high of $800.78. The stock has a market cap of $698.52 billion, a P/E ratio of 108.24, a P/E/G ratio of 1.57 and a beta of 0.37. The company has a current ratio of 1.35, a quick ratio of 0.73 and a debt-to-equity ratio of 1.90.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Tuesday, April 30th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. The firm had revenue of $8.77 billion for the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The business’s revenue for the quarter was up 26.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.62 EPS. On average, equities research analysts forecast that Eli Lilly and Company will post 13.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

LLY has been the topic of a number of analyst reports. The Goldman Sachs Group upped their price objective on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research note on Thursday, April 11th. DZ Bank cut shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target on the stock. in a research report on Wednesday, February 21st. Wells Fargo & Company lifted their price objective on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Finally, Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average price target of $757.95.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.